Latest news with #CyrusPoonawallaGroup
&w=3840&q=100)
Business Standard
04-07-2025
- Business
- Business Standard
Poonawalla Fincorp hits fresh 52-wk high on healthy Q1 biz show; details
Poonawalla Fincorp share price: Non-banking financial company (NBFC) Poonawalla Fincorp share price was in demand on Friday, July 4, 2025, with the stock rising up to 3.68 per cent to hit a fresh 52-week high of ₹483.35 per share. At 1:10 PM, Poonawalla Fincorp share price was trading 2.65 per cent higher at ₹478.50 per share. In comparison, BSE Sensex was trading 0.15 per cent lower at 83,115.80 levels. Follow Stock Market LIVE Updates: Sensex slips 120 pts, Nifty tests 25,350 What fuelled the up move in Poonawalla Fincorp share price today? Poonawalla Fincorp share price hit a fresh high on the back of robust business update in the first quarter of financial year 2026 (Q1FY26). The company's Assets Under Management (AUM) zoomed 52.9 per cent year-on-year (Y-o-Y) and 15.8 per cent quarter-on-quarter (Q-o-Q) to approximately ₹41,250 crore in Q1FY26. Moreover, the company claims that it continues to have ample liquidity of approximately ₹4,450 crore as on June 30, 2025. Poonawalla Fincorp Q4 results Poonawalla Fincorp reported an 81.2 per cent year-on-year (Y-o-Y) decline in net profit to ₹62.33 crore for the quarter ended March 2025 (Q4FY25), as against ₹331.70 crore in the same quarter of the previous year (Q4FY24). However, the company's revenue for the quarter rose 27.46 per cent to ₹1,166.27 crore in Q4FY25, from ₹915 crore in Q4FY24. For the full financial year ended March 2025, the company posted a net loss of ₹98.34 crore, a sharp reversal from a net profit of ₹1,682.75 crore in FY24. About Poonawalla Fincorp Poonawalla Fincorp, formerly known as Magma Fincorp, is a non-banking financial company (NBFC) operating under the umbrella of the Cyrus Poonawalla Group. Recognised for its focus on trust, transparency, and operational excellence, the company is registered with the Reserve Bank of India (RBI) as a systemically important, non-deposit-taking NBFC. A key strength of Poonawalla Fincorp lies in its diversified portfolio of loan products, which includes personal loans, business loans, professional loans, loans against property, and financing for vehicles and equipment. With a strong push toward digital transformation, the company is leveraging technology to simplify its offerings, enhance customer engagement, and ensure faster, more efficient loan disbursements. As part of the Cyrus Poonawalla Group, which also owns the Serum Institute of India (SII), the world's largest vaccine manufacturer, Poonawalla Fincorp benefits from the group's robust legacy and financial stability.
United News of India
14-06-2025
- Health
- United News of India
AP: Serum Institute launches nationwide HPV-Cancer public awareness campaign
Visakhapatnam, June 13 (UNI) : The 'Conquer HPV & Cancer Conclave 2025' was launched here on Friday as part of a nationwide public health initiative by Pune-based Serum Institute of India Pvt. Ltd, part of Cyrus Poonawalla Group is a global leader in vaccine manufacturing. India continues to face a significant burden of HPV-related diseases, particularly cervical cancer, which remains the second most common cancer among women in the country. According to the ICO/IARC Information Centre on HPV and Cancer (2023), India reports over 1.23 lakh new cervical cancer cases and more than 77,000 related deaths annually. Apart from this up to 90 percent of anal cancers & 63 percent of penile cancers are associated with HPV. At the Visakhapatnam event, a panel of medical specialists engaged in an in-depth discussion about the public health implications of HPV. The panel included Dr. Sunanda Rani Gutta – Director & Chief Consultant Gynaecologist, Nikitha Hospital, Visakhapatnam; Dr. Redla Vidya Rama – Prof. of Obstetrics & Gynecology, Andhra Medical College and King George Hospital; Dr. Sai Sunil Kishore Manem – Chief Neonatologist, Medicover Hospital, Vizag. Associate Professor MIMS Medical College, Vizianagaram and Dr. Buddha Murali Santosh – MBBS, DNB, fellowship in Neonatology. Gold medalist. Neonatologist and Pediatrician at Motherly Women and Children Hospital, Vizag The session was moderated by Dr. Vani Isukapalli – Superintendent, King George Hospital, Visakhapatnam. President-IMA, Visakhapatnam. Together, they highlighted the pressing need for awareness, the importance of reaching both adolescents and parents, and the role of healthcare providers in guiding preventive care. The speakers emphasized that HPV is not limited to cervical cancer alone. It is also associated with cancers of the vulva, vagina, anus, penis, and oropharynx, affecting both men and women. With peak HPV infection occurring between ages 15 to 25, early awareness and timely preventive action are essential. With an affordable HPV vaccine now available, it has become still more easier to protect every individual from HPV associated cancers. 'Through these conclaves held across the country, we aim to increase understanding of Human Papillomavirus (HPV) and its link to cervical and other cancers,' said Parag Deshmukh, Executive Director, Serum Institute of India. 'By bringing together medical experts, healthcare workers, and community members, the forum encourages open dialogue and practical steps toward early detection and prevention,' he said. The Visakhapatnam conclave concluded with an open dialogue involving audience members, reinforcing the broader goal of the campaign: to reduce the burden of preventable cancers through informed decision-making and community engagement. The initiative will continue in cities across the country in the coming months, creating platforms for credible voices in healthcare to educate and empower the public. UNI KNR SSP
